Sildenafil Tablet, Film Coated
Product Images NDC 60687-788

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 60687-788). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

33342 0121 10 Nlmimage10 2547928c

Sildenafil 20 mg tablet by American Health Packaging shown from both sides. The white, round tablet is imprinted with "C 89" on one side and the other side is plain. A millimeter scale is displayed for size reference.*

FDA Label Image

Image 01

Sildenafil Tablets, USP 20 mg film-coated tablets in a package of 30 (3 x 10) by American Health Packaging. The label includes dosage strength, quantity, storage instructions, pharmacist dispensing information, and NDC 60687-416-21. The product is Rx only and cautions to keep out of reach of children.*

FDA Label Image

Image 02

Label sheet containing multiple instances of Sildenafil Tablet, USP 20 mg labels from American Health Packaging, Columbus, Ohio. Each label includes the drug name, strength, barcode, and placeholders for lot number and expiration date.*

FDA Label Image

Figure-10 (Sildenafil Fig 10)

A forest plot chart showing placebo-corrected changes in 6-minute walk distance for Sildenafil 20 mg taken three times daily (TID). It compares subgroups including baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary artery pressure, and pulmonary vascular resistance index, with corresponding confidence intervals for each subgroup.*

FDA Label Image

Figure-11 (Sildenafil Fig 11)

A Kaplan-Meier survival plot depicting the percentage of participants without a clinically worsening event over time (days from randomization) for sildenafil versus placebo groups. The x-axis represents time in days, and the y-axis shows the percentage without worsening event, with two survival curves compared across the study duration.*

FDA Label Image

Figure 12 (Sildenafil Fig 12)

A line plot showing the mean change from baseline in meters over 12 weeks for three Sildenafil dosages: 1 mg TID, 5 mg TID, and 20 mg TID. The Y-axis represents change from baseline (meters) and the X-axis shows weeks 4, 8, and 12. Data points include standard error bars indicating variability at each visit.*

FDA Label Image

Fig-6 (Sildenafil Fig 6)

A line graph depicting estimated cumulative mortality rate (%) over a 5-year period for three different dosage groups labeled High dose, Medium dose, and Low dose. The y-axis represents mortality rate percentage from 0 to 25%, and the x-axis represents time in years from 0 to 5. The graph shows mortality rates increasing over time, with High dose having the highest rate, followed by Medium dose and Low dose. Numbers at risk are displayed along the top for each group at various time points.*

FDA Label Image

Fig-8 (Sildenafil Fig 8)

A forest plot chart showing fold change and 90% confidence intervals for various interacting drugs compared to their effects alone. The chart lists drugs such as Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (with three dosage variants), Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. It also provides dosing recommendations, mostly indicating no dose adjustment, except for caution with Ritonavir suggesting coadministration is not recommended. Several pharmacokinetic parameters like AUC, Cmax, INR, and bleeding time are measured.*

FDA Label Image

Figure 9 (Sildenafil Fig 9)

A line graph showing change from baseline (in meters) over weeks 4, 8, and 12 of a study. The graph compares placebo with Sildenafil at 20 mg, 40 mg, and 80 mg doses taken three times daily (TID). A key below identifies the symbols representing each group on the graph.*

FDA Label Image

Figure-7 (Sildenafil Figure 7)

A scatter plot showing fold change and 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) of Sildenafil when co-administered with various interacting drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir. The chart indicates whether dose adjustment is recommended based on these interactions.*

FDA Label Image

Str (Sildenafil Str)

Chemical structure of sildenafil, depicting its molecular conformation and constituent chemical groups as shown in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.